An intermediate alemtuzumab schedule reduces the incidence of mixed chimerism following reduced-intensity conditioning hematopoietic cell transplantation for hemophagocytic lymphohistiocytosis.

@article{Marsh2013AnIA,
  title={An intermediate alemtuzumab schedule reduces the incidence of mixed chimerism following reduced-intensity conditioning hematopoietic cell transplantation for hemophagocytic lymphohistiocytosis.},
  author={Rebecca A Marsh and Mi-Ok Kim and Chun-yan Liu and Denise Bellman and Laura J Hart and Michael S Grimley and Ashish Kumar and Sonata Jodele and Kasiani C Myers and Sharat Chandra and Tom Leemhuis and Parinda A Mehta and Jack Jan Hendrik Bleesing and Stella M. Davies and Michael B. Jordan and Alexandra H. Filipovich},
  journal={Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation},
  year={2013},
  volume={19 11},
  pages={1625-31}
}
Reduced-intensity conditioning (RIC) improves the outcomes of hematopoietic cell transplantation (HCT) in patients with hemophagocytic lymphohistiocytosis (HLH). Proximal (ie, close to graft infusion) dosing of alemtuzumab is associated with a high incidence of mixed chimerism, whereas distal (ie, distant from graft infusion) dosing is associated with less mixed chimerism but more acute graft-versus-host disease (GVHD). The alemtuzumab dose per kilogram of body weight also influences these… CONTINUE READING